Biotechnology

Biotech veteran Habib Dable, who led Acceleron to an $11.5B Merck sale, joins Tyra Biosciences' board, signaling a major push toward commercialization.

Byondis presents two novel ADC platforms at AACR 2026, aiming to solve drug resistance and offer hope for patients unresponsive to immunotherapy.

A European consortium has won €1.3M to develop a precision therapy for chronic urticaria, offering new hope for millions with uncontrolled symptoms.

With $36M secured, Orthogon Therapeutics is advancing a first-in-class oral drug for BK virus, offering a new lifeline for transplant patients.

With a successful $191M IPO, Alamar Biosciences is set to revolutionize diagnostics with its ultra-sensitive proteomics platforms.

New data reveals Mapi Pharma's long-acting GA Depot stabilizes disability in both relapsing and progressive MS, poised for a 2027 European launch.

Patients, doctors, and researchers unite for a grueling ride across Iceland, raising funds and hope for a future free from multiple myeloma.

A new oral drug candidate for lupus and RA emerges as Totus Medicines uses its AI platform to rapidly develop a first-in-class inhibitor for the elusive IRF5 protein.

Biopharma veteran Glenn Gormley joins Aktis's board, bringing deep ADC expertise to guide the company's next-gen radiopharmaceutical pipeline.

San Diego's Blacksmith Medicines will present promising data on its FEN1 inhibitor, a new drug targeting a notoriously difficult class of enzymes.

A new partnership combines live biopsy analysis with agentic AI, seeking to predict immunotherapy response and solve why only 1 in 5 patients benefit.

A Boston biotech says its new AI platform moves beyond correlation to find the true biological causes of disease, promising a new era for medicine.

A novel immunotherapy tames a potent but toxic cancer-fighting agent by locking it inside tumors, offering new hope for patients with resistant cancers.

Quintara Biosciences launches AmpValue, a $4.99 overnight sequencing service set to disrupt biotech by making advanced, full-length data accessible to all.

A new oral therapy shows a 76% response rate in a hard-to-treat lung cancer, offering a powerful new first-line option for patients with this rare disease.

Biopharma leader Dr. Gavin Barnard joins ATUM as CSO, aiming to leverage AI and advanced tech to fast-track complex therapies from the lab to the clinic.

With founder Frédéric Mascha as Executive Chairman and new CEO Renaud Sermondade, Juvisé Pharmaceuticals is poised for major M&A-fueled global expansion.

Inventia Life Science's new RASTRUM Validated Solutions offer standardized 3D models to tackle the reproducibility crisis in pharmaceutical R&D.

A Chinese biotech has won a key approval for a novel antibody designed to fight deadly leukemias with enhanced safety, marking a new frontier in cancer care.

Despite major cost cuts and growth in key divisions, DSS, Inc. struggles to convince Wall Street. Can a biotech spin-off finally unlock its true value?